All
An Expert Discusses PARP Inhibition, Vaccines and Emerging Therapies in Kidney Cancer
November 3rd 2019The field of kidney cancer treatment could soon be expanding thanks to the inclusion of PARP inhibitors, vaccination-based strategies and emerging therapies such as Fotivda (tivozanib), according to research presented at the 2019 Kidney Cancer Research Summit.
What You Need to Know About the FDA's Approval of Zejula
November 1st 2019The Food and Drug Administration’s recent approval of Zejula for certain patients with advanced ovarian, fallopian tube or primary peritoneal cancer was the first PARP inhibitor approved for the treatment, not the maintenance, of these women.